Soleno Therapeutics Inc. experienced a sharp pre-market decline, with its stock plummeting 8.32% during Thursday's pre-market trading session.
The significant drop follows a notable analyst action, as TD Cowen cut its price target on Soleno Therapeutics to $85 from $120. Such a substantial reduction in valuation expectations from a major financial institution often triggers negative sentiment among investors, leading to selling pressure.
While the company recently announced a change in its financial leadership, the market's reaction appears to be dominated by the revised and lower price target, reflecting concerns or a reassessment of the company's future earnings potential or commercial prospects.
Comments